Kim Margolin MD
Hematologic Oncology, Melanoma
Professor of Medicine, Stanford University Division of Oncology
Join to view full profile
2121 Santa Monica BlvdSanta Monica, CA 90404
Phone+1 310-829-8317
Fax+1 310-315-6143
Dr. Margolin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1985- City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1983
Yale-New Haven Medical CenterResidency, Internal Medicine, 1979 - 1982
Stanford University School of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 1982 - 2027
WA State Medical License 2008 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
Publications & Presentations
PubMed
- Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1.Katie M Campbell, Daniel G Chen, Zaid E Bustami, Nataly Naser Al Deen, Egmidio Medina
Cancer Discovery. 2026-09-01 - 6 citationsIntratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from ...Mohammed M Milhem, Yousef Zakharia, Diwakar Davar, Elizabeth I Buchbinder, Theresa Medina
Cancer. 2025-08-01 - 1 citationsA Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy.Debarati Bhanja, Junjia Zhu, Hannah Wilding, Jorge Benavides-Vasquez, Leonardo de Macedo Filho
Clinical Cancer Research. 2025-08-01
Journal Articles
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaIgor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Authored Content
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Press Mentions
FDA Approves Cosibelimab-Ipdl for Advanced Cutaneous Squamous Cell CarcinomaDecember 17th, 2024- Oncologists Celebrate the Legacy of Dr. Jeffrey S. Weber, “the Consummate Physician-Scientist”August 26th, 2024
- What Is the Latest Research on the Form of Cancer Jimmy Carter Has?March 3rd, 2023
Grant Support
- Academic Industry AwardMelanoma Research Alliance, Altor Bioscience2012–2014
Other Languages
- Spanish, French, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: